• Study Resource
  • Explore Categories
    • Arts & Humanities
    • Business
    • Engineering & Technology
    • Foreign Language
    • History
    • Math
    • Science
    • Social Science

    Top subcategories

    • Advanced Math
    • Algebra
    • Basic Math
    • Calculus
    • Geometry
    • Linear Algebra
    • Pre-Algebra
    • Pre-Calculus
    • Statistics And Probability
    • Trigonometry
    • other →

    Top subcategories

    • Astronomy
    • Astrophysics
    • Biology
    • Chemistry
    • Earth Science
    • Environmental Science
    • Health Science
    • Physics
    • other →

    Top subcategories

    • Anthropology
    • Law
    • Political Science
    • Psychology
    • Sociology
    • other →

    Top subcategories

    • Accounting
    • Economics
    • Finance
    • Management
    • other →

    Top subcategories

    • Aerospace Engineering
    • Bioengineering
    • Chemical Engineering
    • Civil Engineering
    • Computer Science
    • Electrical Engineering
    • Industrial Engineering
    • Mechanical Engineering
    • Web Design
    • other →

    Top subcategories

    • Architecture
    • Communications
    • English
    • Gender Studies
    • Music
    • Performing Arts
    • Philosophy
    • Religious Studies
    • Writing
    • other →

    Top subcategories

    • Ancient History
    • European History
    • US History
    • World History
    • other →

    Top subcategories

    • Croatian
    • Czech
    • Finnish
    • Greek
    • Hindi
    • Japanese
    • Korean
    • Persian
    • Swedish
    • Turkish
    • other →
 
Profile Documents Logout
Upload
Urine Drug Monitoring: Opioids
Urine Drug Monitoring: Opioids

... that addictive disorders occur in 10% of the general population.9 A clinical study concerning long-term opioid therapy for non-cancer pain in patients who had been selected based on low risk of addiction found that a very small number of these patients developed addiction.10 For patients outside the ...
Demystifying Analytical Approaches for Urine Drug Testing to
Demystifying Analytical Approaches for Urine Drug Testing to

... and may be more likely to be dilute in a sick than a healthy population. The time of urine collection relative to the last drug dose, the pattern and dosing of drug use, the unique pharmacokinetics of the drug in an individual patient, the quality of the specimen provided for testing, and the analyt ...
Radius Health, Inc. - Nasdaq`s INTEL Solutions
Radius Health, Inc. - Nasdaq`s INTEL Solutions

... partnership, and (ii) the transferee agrees in writing to be subject to the terms of Sections 3.1, 3.2, 3.3 and 3.10 hereof to the same extent as if such transferee were originally a signatory to this Agreement. If in an opinion of counsel or as reasonably concluded from the facts set forth in the r ...
Pharmacy Law Review 2010
Pharmacy Law Review 2010

... If an article is alleged to be misbranded because the labeling or advertising is misleading, then in determining whether the labeling or advertising is misleading there shall be taken into account (among other things) not only representations made or suggested by statement, word, design, device, or ...
Newsletter What’s Inside
Newsletter What’s Inside

... use of the exosome secretion mechanism of host cells to achieve stabilization within the host organism and introduce the infection effectively. I am impressed with the depth of nanoparticles in Mother Nature. From another viewpoint, that of clarifying the structure and function of nanoparticles in n ...
Product Monograph
Product Monograph

Pharmacy Therapeutics Policies and Procedures
Pharmacy Therapeutics Policies and Procedures

... New formulations of drugs currently on formulary will be added to the Drug  Formulary by Pharmacy Administration if they are cost‐neutral.  New formulations that are expected to have a significant cost impact are  brought to the P&T Committee for consideration.  An example is a new  product formulat ...
Local Anesthesia in Dentistry
Local Anesthesia in Dentistry

... An article by Haas and Lennon published in 1995 seems to be the original source for this controversy11. This paper analyzed 143 cases reported to the Royal College of Dental Surgeons of Ontario (RCDSO) over a 21-year period. The results from their analysis seemed to indicate that 4% anesthetics had ...
Vitae Pharmaceuticals, Inc
Vitae Pharmaceuticals, Inc

... has a predicted human oral dosing schedule of once-a-day. VTP-43742 also demonstrated superiority in an animal model of multiple sclerosis in direct comparison to an IL-17A monoclonal antibody. Vitae has filed an Investigational New Drug Application with the U.S. Food and Drug Administration for VTP ...
vitae pharmaceuticals, inc. - corporate
vitae pharmaceuticals, inc. - corporate

... ROR isotypes, and has a predicted human oral dosing schedule of once-a-day. VTP-43742 also demonstrated superiority in an animal model of multiple sclerosis in direct comparison to an IL-17A monoclonal antibody. Vitae has filed an Investigational New Drug Application with the U.S. Food and Drug Admi ...
Ingen diastitel
Ingen diastitel

... Evaluation of a new drug ...
Prescribing for Pregnant or Lactating Women
Prescribing for Pregnant or Lactating Women

Pharmacy Compounding: Defining the New Landscape for Safe
Pharmacy Compounding: Defining the New Landscape for Safe

... the public that companies like NECC are not local compounding pharmacies but instead are large-volume production facilities that ship to intermediaries, not patients, across state lines. This is no longer an uncommon process, because of demand for drugs in shortage and for drugs with alternate route ...
Mifepristone: Expanding Women`s Options for Early Abortion in the
Mifepristone: Expanding Women`s Options for Early Abortion in the

... announced that it had no intention of marketing the drug in the U.S. or any other country where the company perceived that political and social conditions were unreceptive to the drug. The George H. W. Bush administration, with its overall hostility to abortion, took the additional step of placing m ...
Pharmacovigilance of drug allergy and hypersensitivity using
Pharmacovigilance of drug allergy and hypersensitivity using

Clinical Guidance for the use of medicinal cannabis products in
Clinical Guidance for the use of medicinal cannabis products in

AusPAR Lenvatinib mesilate - Therapeutic Goods Administration
AusPAR Lenvatinib mesilate - Therapeutic Goods Administration

Influence of applying different units of measurement on reporting
Influence of applying different units of measurement on reporting

... antimicrobial consumption by applying three different sets of nationally established animal defined daily dosages to the same antimicrobial drug delivery dataset of Dutch pigs in 2012. Methods: Delivery information for the complete Dutch pig sector for the year 2012 reported to the Netherlands Veter ...
Collagenase clostridium histolyticum
Collagenase clostridium histolyticum

amikai
amikai

... KAI Pharmaceuticals may lack financial resources to complete development of product candidates, regulatory agencies may interpret the results of studies differently than Daiichi Sankyo and KAI Pharmaceuticals, competing products may be more successful, demand for new pharmaceutical products may decr ...
Molecular imaging with SPECT as a tool for drug
Molecular imaging with SPECT as a tool for drug

... administered to subjects in the nano to picomolar range. Drugs administrated at these tiny quantities do not produce any pharmacological effects which reduce the risk of serious adverse effects in human volunteers or patients. Depending on the ligands and radionuclides used, it is possible to genera ...
Guidance for Industry Irritable Bowel Syndrome — Clinical Evaluation of Products for Treatment
Guidance for Industry Irritable Bowel Syndrome — Clinical Evaluation of Products for Treatment

... represent and capture the intended measurement concept and are meaningful, appropriate, and interpretable relative to the intended measurement concept(s), population, and use. Although input from experts in the field and literature reviews are an important and necessary first component in drafting t ...
Drug Discovery and Creation
Drug Discovery and Creation

... Upper Saddle River, New Jersey 07458 All rights reserved. ...
The Effect of Overencapsulation on Disintegration and
The Effect of Overencapsulation on Disintegration and

... The model-independent similarity factor (f2) may be used to compare the dissolution profiles of two drug products (see Equation 1). This equation measures the similarity in the percent dissolution between the two curves. An f2 greater than 50 implies that two dissolution profiles are similar9. The U ...
PERCUTANEOUS DRUG DELIVERY SYSTEMS FOR IMPROVING ANTIFUNGAL THERAPY EFFECTIVENESS: A REVIEW
PERCUTANEOUS DRUG DELIVERY SYSTEMS FOR IMPROVING ANTIFUNGAL THERAPY EFFECTIVENESS: A REVIEW

... The physicochemical and pharmacokinetic properties of these drugs plus their inherent antifungal potency determine their efficacy, so they are important issues to consider in pre-development stage. FLZ is more polar than other azoles, slightly soluble in water (5 mg/mL at 37ºC), metabolically stable ...
< 1 ... 24 25 26 27 28 29 30 31 32 ... 193 >

Biosimilar

A biosimilar (also known as follow-on biologic or subsequent entry biologic) is a biologic medical product which is a copy of an original product that is manufactured by a different company. Biosimilars are officially approved versions of original ""innovator"" products, and can be manufactured when the original product's patent expires. Reference to the innovator product is an integral component of the approval.Unlike the more common small-molecule drugs, biologics generally exhibit high molecular complexity, and may be quite sensitive to changes in manufacturing processes. Follow-on manufacturers do not have access to the originator's molecular clone and original cell bank, nor to the exact fermentation and purification process, nor to the active drug substance. They do have access to the commercialized innovator product.Drug related authorities such as European Medicines Agency (EMA), Food and Drug Administration (FDA), and Health Canada hold their own guidance on requirements for demonstration of the similar nature of two biological products in terms of safety and efficacy. According to them, analytical studies that demonstrate that the biological product is highly similar to the reference product notwithstanding minor differences in clinically inactive components; animal studies (including the assessment of toxicity); and a clinical study or studies (including the assessment of immunogenicity and pharmacokinetics or pharmacodynamics) that are sufficient to demonstrate safety, purity, and potency in one or more appropriate conditions of use for which the reference product is licensed and intended to be used and for which licensure is sought for the biological product.In case of a monoclonal antibody-containing medicinal product, such as Remsima, extensive physicochemical and biological characterization for it and its reference product Remicade was conducted in order to demonstrate their highly similar properties. Consequently, EMA have granted a marketing authorisation for only a few numbers of biosimilars since 2006 including a monoclonal antibody which is recently approved. Meanwhile, on March 6, 2015, the FDA approved the United States's first biosimilar product, the biosimilar filgrastim Zarxio.
  • studyres.com © 2025
  • DMCA
  • Privacy
  • Terms
  • Report